Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus chemoradiotherapy for newly diagnosed locally advanced laryngopharyngeal carcinoma
ChiCTR2100046726Phase 2Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in Laryngeal squamous cell carcinoma (LSCC) (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoints: Objective response rate and Safety and tolerability. Started Jun 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Laryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on ChiCTR2100046726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046726.